Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
37709 | 50 | 27.8 | 81% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
51 | 3 | HEMATOLOGY//BONE MARROW TRANSPLANTATION//BLOOD | 91443 |
2713 | 2 | METHYLSULFONYLMETHANE//SEROFENDIC ACID//N ACETYL S N METHYLCARBAMOYLCYSTEINE | 3317 |
37709 | 1 | SEROFENDIC ACID//2E N 2 MORPHOLIN 4 YLETHYL CINNAMIDE//3 HYDROXY FURANE 25H ONE | 50 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | SEROFENDIC ACID | authKW | 7980001 | 28% | 93% | 14 |
2 | 2E N 2 MORPHOLIN 4 YLETHYL CINNAMIDE | authKW | 610715 | 2% | 100% | 1 |
3 | 3 HYDROXY FURANE 25H ONE | authKW | 610715 | 2% | 100% | 1 |
4 | ANTI ISCHAEMIC ACTIVITY | authKW | 610715 | 2% | 100% | 1 |
5 | ASCORBIC ACID ANALOGUE | authKW | 610715 | 2% | 100% | 1 |
6 | ATISANE NEUROPROTECTIVE | authKW | 610715 | 2% | 100% | 1 |
7 | CINNAMIDE DERIVATIVES | authKW | 610715 | 2% | 100% | 1 |
8 | FURAN 2 ONES DERIVATIVES | authKW | 610715 | 2% | 100% | 1 |
9 | HYDROXYCINNAMIC ACID HYDRAZIDE | authKW | 610715 | 2% | 100% | 1 |
10 | PHARM PHARMACEUT SCI NEUROPHARMACOL | address | 610715 | 2% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Crystallography | 323 | 22% | 0% | 11 |
2 | Chemistry, Medicinal | 137 | 16% | 0% | 8 |
3 | Pharmacology & Pharmacy | 121 | 30% | 0% | 15 |
4 | Neurosciences | 28 | 16% | 0% | 8 |
5 | Chemistry, Organic | 27 | 12% | 0% | 6 |
6 | Ornithology | 16 | 2% | 0% | 1 |
7 | Chemistry, Inorganic & Nuclear | 10 | 6% | 0% | 3 |
8 | Biochemistry & Molecular Biology | 4 | 12% | 0% | 6 |
9 | Clinical Neurology | 1 | 4% | 0% | 2 |
10 | Medicine, General & Internal | 1 | 4% | 0% | 2 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PHARM PHARMACEUT SCI NEUROPHARMACOL | 610715 | 2% | 100% | 1 |
2 | NEUROSCI DRUG DISCOVERY | 159162 | 14% | 4% | 7 |
3 | GRP RECH PHARMACOCHIM | 111035 | 4% | 9% | 2 |
4 | BIO ANALYT CHEM | 61070 | 2% | 10% | 1 |
5 | PHARM CLIN BIOTECH | 38168 | 2% | 6% | 1 |
6 | TSUKUBA S | 15404 | 8% | 1% | 4 |
7 | CHEMICOPHARMACOL SCI | 12721 | 2% | 2% | 1 |
8 | AREA NUTR | 12462 | 2% | 2% | 1 |
9 | CHIM THER EUT | 4703 | 4% | 0% | 2 |
10 | ANIM | 4422 | 10% | 0% | 5 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CARDIOVASCULAR DRUG REVIEWS | 1452 | 2% | 0% | 1 |
2 | CHINESE JOURNAL OF STRUCTURAL CHEMISTRY | 1334 | 6% | 0% | 3 |
3 | JOURNAL OF PHARMACOLOGICAL SCIENCES | 1048 | 4% | 0% | 2 |
4 | ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE | 889 | 10% | 0% | 5 |
5 | SOUTH AFRICAN JOURNAL OF CHEMISTRY-SUID-AFRIKAANSE TYDSKRIF VIR CHEMIE | 837 | 2% | 0% | 1 |
6 | SEMAINE DES HOPITAUX | 718 | 4% | 0% | 2 |
7 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 588 | 6% | 0% | 3 |
8 | FARMACO | 347 | 2% | 0% | 1 |
9 | ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS | 319 | 6% | 0% | 3 |
10 | BIOLOGICAL & PHARMACEUTICAL BULLETIN | 282 | 4% | 0% | 2 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SEROFENDIC ACID | 7980001 | 28% | 93% | 14 | Search SEROFENDIC+ACID | Search SEROFENDIC+ACID |
2 | 2E N 2 MORPHOLIN 4 YLETHYL CINNAMIDE | 610715 | 2% | 100% | 1 | Search 2E+N+2+MORPHOLIN+4+YLETHYL+CINNAMIDE | Search 2E+N+2+MORPHOLIN+4+YLETHYL+CINNAMIDE |
3 | 3 HYDROXY FURANE 25H ONE | 610715 | 2% | 100% | 1 | Search 3+HYDROXY+FURANE+25H+ONE | Search 3+HYDROXY+FURANE+25H+ONE |
4 | ANTI ISCHAEMIC ACTIVITY | 610715 | 2% | 100% | 1 | Search ANTI+ISCHAEMIC+ACTIVITY | Search ANTI+ISCHAEMIC+ACTIVITY |
5 | ASCORBIC ACID ANALOGUE | 610715 | 2% | 100% | 1 | Search ASCORBIC+ACID+ANALOGUE | Search ASCORBIC+ACID+ANALOGUE |
6 | ATISANE NEUROPROTECTIVE | 610715 | 2% | 100% | 1 | Search ATISANE+NEUROPROTECTIVE | Search ATISANE+NEUROPROTECTIVE |
7 | CINNAMIDE DERIVATIVES | 610715 | 2% | 100% | 1 | Search CINNAMIDE+DERIVATIVES | Search CINNAMIDE+DERIVATIVES |
8 | FURAN 2 ONES DERIVATIVES | 610715 | 2% | 100% | 1 | Search FURAN+2+ONES+DERIVATIVES | Search FURAN+2+ONES+DERIVATIVES |
9 | HYDROXYCINNAMIC ACID HYDRAZIDE | 610715 | 2% | 100% | 1 | Search HYDROXYCINNAMIC+ACID+HYDRAZIDE | Search HYDROXYCINNAMIC+ACID+HYDRAZIDE |
10 | CINNAMIDE | 422798 | 6% | 23% | 3 | Search CINNAMIDE | Search CINNAMIDE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | IOROI, T , TAGUCHI, K , IZUMI, Y , TAKADA-TAKATORI, Y , AKAIKE, A , KUME, T , (2013) PROTECTIVE EFFECT OF SEROFENDIC ACID, ADMINISTERED INTRAVENOUSLY, ON CEREBRAL ISCHEMIA-REPERFUSION INJURY IN RATS.BRAIN RESEARCH. VOL. 1532. ISSUE . P. 99-105 | 9 | 33% | 0 |
2 | DOI, Y , LIANG, JF , KUNO, R , ZANG, GQ , KAWANOKUCHI, J , YAWATA, I , TAKEUCHI, H , MIZUNO, T , SUZUMURA, A , (2006) THE DIRECT AND INDIRECT EFFECTS OF SEROFENDIC ACID ON NEUROPROTECTION.INTEGRATED MOLECULAR MEDICINE FOR NEURONAL AND NEOPLASTIC DISORDERS. VOL. 1086. ISSUE . P. 91-103 | 7 | 44% | 0 |
3 | ZHONG, Y , ZHANG, XP , WU, B , (2012) (E)-1-{4-[BIS(4-METHOXYPHENYL)METHYL]PIPERAZIN-1-YL}-3-(3,4-DIETHOXYPHENYL)PROP-2-EN-1-ONE ETHANOL DISOLVATE.ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS. VOL. 68. ISSUE . P. O298 -U1798 | 3 | 75% | 0 |
4 | ZHONG, Y , ZHANG, XP , WU, B , (2012) (E)-1-{4-[BIS(4-BROMOPHENYL)METHYL]PIPERAZIN-1-YL}-3-(4-ETHOXY-3-METHOXYPHENYL)PROP-2-EN-1-ONE.ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE. VOL. 68. ISSUE . P. - | 3 | 75% | 0 |
5 | AKAO, M , TAKEDA, T , KITA, T , KUME, T , AKAIKE, A , (2007) SEROFENDIC ACID, A SUBSTANCE EXTRACTED FROM FETAL CALF SERUM, AS A NOVEL DRUG FOR CARDIOPROTECTION.CARDIOVASCULAR DRUG REVIEWS. VOL. 25. ISSUE 4. P. 333-341 | 9 | 24% | 3 |
6 | NAKAMURA, T , KUME, T , KATSUKI, H , NIIDOME, T , SUGIMOTO, H , AKAIKE, A , (2008) PROTECTIVE EFFECT OF SEROFENDIC ACID ON ISCHEMIC INJURY INDUCED BY OCCLUSION OF THE MIDDLE CEREBRAL ARTERY IN RATS.EUROPEAN JOURNAL OF PHARMACOLOGY. VOL. 586. ISSUE 1-3. P. 151-155 | 8 | 24% | 6 |
7 | ZHONG, Y , WU, B , (2011) (E)-1-{4-[BIS(4-METHOXYPHENYL)METHYL]PIPERAZIN-1-YL}-3-(4-METHYLPHENYL)PROP-2-EN-1-ONE.ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS. VOL. 67. ISSUE . P. O2791 -+ | 3 | 60% | 1 |
8 | ZHONG, Y , ZHANG, XP , WU, B , (2011) (E)-1-{4-[BIS(4-BROMOPHENYL)METHYL]PIPERAZIN-1-YL}-3-(4-BROMOPHENYL)PROP2-EN-1-ONE.ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE. VOL. 67. ISSUE . P. O3358 -U242 | 3 | 60% | 0 |
9 | ZHONG, Y , ZHANG, XP , WU, B , (2011) (E)-1-(4-BENZHYDRYLPIPERAZIN-1-YL)-3-(2-ETHOXYPHENYL)PROP-2-EN-1-ONE.ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE. VOL. 67. ISSUE . P. O3200 -U1917 | 3 | 60% | 0 |
10 | ZHONG, Y , WU, B , (2011) (E)-1-(4-BENZHYDRYLPIPERAZIN-1-YL)-3-(3,4-DIETHOXYPHENYL)PROP-2-EN-1-ONE ETHANOL MONOSOLVATE.ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE. VOL. 67. ISSUE . P. O2992 -U1017 | 3 | 60% | 0 |
Classes with closest relation at Level 1 |